| amount |
phenotype |
2 |
2 |
$5>$0.20 |
| AMP |
drug |
2 |
3 |
amphetamine |
| AMPA receptor |
drug |
11 |
8 |
AMPA, AMPA receptor subunit, AMPA receptors, AMPA-receptor, AMPAR, glutamate receptor AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor |
| amphetamine |
drug |
25 |
14 |
AMP, AMPH, amphetamine, amphetamines |
| amphetamines |
drug |
12 |
6 |
Amphetamine, stimulants |
| amphetamine-type stimulants |
drug |
2 |
— |
ATS, amphetamine-type stimulants |
| AMPK |
gene |
7 |
6 |
AMP-activated kinase, AMP-activated protein kinase, AMPK, AMPK signaling, PRKAA1, PRKAA1/PRKAA2 complex, PRKAA2, hypothalamic AMPK |
| amplitude |
phenotype |
5 |
3 |
ERP amplitude, amplitude, beta excess amplitude |
| Ampure XP beads |
drug |
4 |
1 |
AMPure XP, Ampure XP beads |
| AMR |
cohort |
7 |
1 |
Admixed American, American admixed populations, American ancestry |
| amygdala habituation |
phenotype |
2 |
1 |
amygdala habituation to threat-related stimuli, habituation of amygdala response |
| amygdala volume |
phenotype |
3 |
2 |
|
| Amyloid beta |
drug |
9 |
9 |
Aβ, Aβ oligomers, oligomeric Aβ |
| Amyloid-beta |
drug |
3 |
3 |
Aβ, Aβ proteins, aggregated Aβ, anti-Aβ antibodies, beta-amyloid |
| Amyloid-beta peptide |
drug |
4 |
4 |
Aβ, Aβ peptides, amyloid-β |
| amyloid pathology |
phenotype |
3 |
2 |
amyloid aggregation |
| amyloid plaques |
phenotype |
6 |
5 |
Aβ plaques, extracellular amyloid plaques |
| amyotrophic lateral sclerosis |
phenotype |
13 |
3 |
ALS, Amyotrophic lateral sclerosis, Lou Gehrig’s disease, familial ALS, motor neuron disease |
| AN |
phenotype |
5 |
4 |
Anorexia Nervosa, Anorexia nervosa, anorexia nervosa |
| anaemia |
phenotype |
4 |
1 |
anemia |
